News
Insilico Advances Rentosertib into Phase III Trial for Idiopathic Pulmonary Fibrosis
By targeting TNIK, Insilico’s Rentosertib aims to halt or reverse fibrotic processes, offering a disease-modifying treatment for patients with idiopathic pulmonary fibrosis (IPF).


